> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pharmasol Permanent Injunction Approved
- URL: https://www.fdaweb.com/pharmasol-permanent-injunction-approved/
- Published: 2023-12-14T12:00:00.000Z
- Updated: 2026-09-14T14:18:38.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155997

The Massachusetts federal court has approved a consent decree of permanent injunction against Pharmasol Corp. and its president **Marc Badia** for distributing adulterated drugs. An FDA [statement](https://www.fda.gov/news-events/press-announcements/federal-court-enters-consent-decree-against-pharmasol-distributing-adulterated-drugs?ref=fdaweb.com) says a complaint that was filed with the consent decree by the Department of Justice says the company and Bardia failed to: **(1)** fully investigate errors and ensure that the responsibilities and procedures applicable to the quality control unit are in writing and fully followed, including reporting drug defects to consumers; **(2)** follow written procedures that describe the handling of written and oral complaints regarding a drug product; and **(3)** adequately clean and maintain equipment.

Pharmasol manufactures and distributes over-the-counter drugs and human and animal prescription drugs, FDA says. It is under contract with multiple drug companies.

A 2022 FDA inspection found that a majority of the inspectional observations were repeated from past inspections that were detailed in a 2019 Warning Letter, the agency says. The Warning Letter cited consumer complaints of product leakage out of the container and the company’s failure to investigate. “Despite repeated warnings, the company and Badia continued to violate the law,” FDA says.

The decree prohibits Pharmasol and Badia from directly or indirectly manufacturing, preparing, processing, packing, repacking, receiving, labeling, holding, and/or distributing any drug, at or from their facilities, until they meet certain requirements to ensure that Pharmasol complies with the Federal Food, Drug, and Cosmetic Act, FDA’s regulations, and the decree, and the company and Badia receive written notice from FDA that they appear to be complying with the requirements.